Patents by Inventor Takayoshi Hamamoto
Takayoshi Hamamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8569238Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.Type: GrantFiled: March 18, 2013Date of Patent: October 29, 2013Assignees: The Chemo-Sero-Therapeutic Research Institute, Ginkyo Academy Kumamoto Health Science University, National University Corporation Kumamoto UniversityInventors: Shintaro Kamei, Asami Shindome, Takayoshi Hamamoto, Hiroaki Maeda, Masaki Hirashima, Sachio Okuda, Misako Umehashi, Sachie Ogawa, Megumi Imuta, Norio Akaike, Kazuo Takahama, Ryoko Wada
-
Publication number: 20130224179Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.Type: ApplicationFiled: March 18, 2013Publication date: August 29, 2013Inventors: SHINTARO KAMEI, ASAMI SHINDOME, TAKAYOSHI HAMAMOTO, HIROAKI MAEDA, MASAKI HIRASHIMA, SACHIO OKUDA, MISAKO UMEHASHI, SACHIE OGAWA, MEGUMI IMUTA, NORIO AKAIKE, KAZUO TAKAHAMA, RYOKO WADA
-
Publication number: 20130041137Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.Type: ApplicationFiled: October 12, 2011Publication date: February 14, 2013Inventors: Kenji SOEJIMA, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Publication number: 20120225818Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.Type: ApplicationFiled: August 5, 2010Publication date: September 6, 2012Applicants: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, GINKYO ACADEMY KUMAMOTO HEALTH SCIENCE UNIVERSITYInventors: Shintaro Kamei, Asami Shindome, Takayoshi Hamamoto, Hiroaki Maeda, Masaki Hirashima, Sachio Okuda, Misako Umehashi, Sachie Ogawa, Megumi Imuta, Norio Akaike, Kazuo Takahama, Ryoko Wada
-
Patent number: 8067221Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.Type: GrantFiled: April 16, 2008Date of Patent: November 29, 2011Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Patent number: 7575872Abstract: It is intended to provide an antibody showing immunoreactivity selectively to ADAMTS-13 and applications of this antibody in epitope analysis or diagnosis of an ADAMTS-13 autoantibody-positive patient. Alternatively, it is intended to provide a process for producing and use of a modified ADAMTS-13 molecule partially deleted aiming at the application in pharmaceutical products. An antibody specific for ADAMTS-13 which can be obtained from a warm-blooded animal immunized and sensitized with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; a process for producing an antibody comprising a step of immunizing and sensitizing a warm-blooded animal with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; use of the above-described antibody including a method of detecting and purifying ADAMTS-13; and a modified ADAMTS-13 molecule partially deleted are provided.Type: GrantFiled: September 25, 2003Date of Patent: August 18, 2009Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Publication number: 20080254527Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.Type: ApplicationFiled: April 16, 2008Publication date: October 16, 2008Inventors: Kenji SOEJIMA, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Patent number: 7361748Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.Type: GrantFiled: December 8, 2005Date of Patent: April 22, 2008Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Publication number: 20060251655Abstract: It is intended to provide an antibody showing immunoreactivity selectively to ADAMTS-13 and applications of this antibody in epitope analysis or diagnosis of an ADAMTS-13 autoantibody-positive patient. Alternatively, it is intended to provide a process for producing and use of a modified ADAMTS-13 molecule partially deleted aiming at the application in pharmaceutical products. An antibody specific for ADAMTS-13 which can be obtained from a warm-blooded animal immunized and sensitized with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; a process for producing an antibody comprising a step of immunizing and sensitizing a warm-blooded animal with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; use of the above-described antibody including a method of detecting and purifying ADAMTS-13; and a modified ADAMTS-13 molecule partially deleted are provided.Type: ApplicationFiled: September 25, 2003Publication date: November 9, 2006Inventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Patent number: 7112666Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val, and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.Type: GrantFiled: April 25, 2002Date of Patent: September 26, 2006Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Publication number: 20060073569Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.Type: ApplicationFiled: December 8, 2005Publication date: April 6, 2006Inventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Publication number: 20040214275Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease.Type: ApplicationFiled: October 22, 2003Publication date: October 28, 2004Inventors: Kenji Soejima, Noriko Mimura, Hiroaki Maeda, Chikateru Nozaki, Takayoshi Hamamoto, Tomohiro Nakagaki
-
Publication number: 20040197852Abstract: A process for preparing a peptide fragment having a cell death-inhibitory activity is provided. In order to obtain a selenoprotein P fragment having a cell death-inhibitory activity, full-length selenoprotein P was reacted with various serine proteinases and the resulting fragments were electrophoresed and assessed for a cell death-inhibitory activity. A process for preparing a selenoprotein P fragment was established by identifying an enzyme that produced bands corresponding to a molecular weight of not more than 3.5×104 in electrophoresis. A process for preparing a peptide fragment having a cell death-inhibitory activity according to the present invention may be used for amelioration, treatment and prevention of diseases caused by cell death and for more efficient production of useful living substances.Type: ApplicationFiled: February 9, 2004Publication date: October 7, 2004Inventors: Shinataro Kamei, Takayoshi Hamamoto, Masaki Hirashima, Hiroaki Maeda, Hazuhiko Takahashi
-
Patent number: 5811279Abstract: A method for activating prothrombin to thrombin is presented which comprises treating an aqueous solution containing prothrombin with polyethylene glycol in the presence or absence of the calcium salt. The method enables conversion of prothrombin to thrombin in the absence of thromboplastin and allows for preparation of thrombin on an industrially large scale from easily available starting materials.Type: GrantFiled: August 1, 1997Date of Patent: September 22, 1998Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Hiroshi Kaetsu, Jun Mizuguchi, Takayoshi Hamamoto
-
Patent number: 5378612Abstract: A culture medium without or with a low level of protein for culturing a transformed animal cell capable of continuously producing a protein prepared by using a genetic engineering technique, which contains a nonionic surfactant and cyclodextrin, and a method for producing a protein which comprises culturing a transformed animal cell capable of producing the desired protein prepared by using a genetic engineering technique in the culture medium.Type: GrantFiled: December 28, 1992Date of Patent: January 3, 1995Assignees: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Teijin LimitedInventors: Kazuyuki Nakashima, Izumi Mimaki, Takayoshi Hamamoto, Kenichi Masuda